Description

Stivarga (Regorafenib): Uses, Benefits, and Important Safety Information

Stivarga (regorafenib) is an oral prescription medication used to treat certain types of advanced cancers. It belongs to a class of targeted therapies known as multikinase inhibitors, which work by blocking specific proteins involved in tumor growth and the formation of new blood vessels that feed cancer cells.

What Is Stivarga Used For?

Stivarga is commonly prescribed for patients with:

• Metastatic colorectal cancer (CRC) that has progressed after other treatments.
• Gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have stopped responding to previous therapies.
• Hepatocellular carcinoma (HCC), the most common form of liver cancer, in patients who have previously received treatment.

By targeting multiple pathways involved in cancer progression, Stivarga can help slow disease growth and improve disease control in eligible patients.

How Does Stivarga Work?

Cancer cells rely on specific signaling pathways to grow, spread, and develop new blood vessels. Stivarga blocks several enzymes known as kinases that are involved in these processes. This targeted action may help reduce tumor growth and limit the cancer’s ability to spread.

Administration and Dosage

Stivarga is taken orally, usually once daily for three weeks followed by one week off treatment, forming a four-week treatment cycle. Patients should take the medication exactly as prescribed by their healthcare provider and follow all dietary and administration instructions.

Potential Side Effects

Like all cancer treatments, Stivarga may cause side effects. Common side effects include:

• Fatigue and weakness
• Hand-foot skin reaction
• High blood pressure
• Diarrhea
• Loss of appetite
• Weight loss
• Mouth sores
• Hoarseness

Some patients may experience serious side effects, including liver problems, severe bleeding, or heart-related complications. Regular monitoring by a healthcare team is essential during treatment.

Important Safety Considerations

Patients should inform their healthcare provider about all medications, supplements, and medical conditions before starting treatment. Liver function tests and blood pressure monitoring are often recommended throughout therapy.

It is important to report any unusual symptoms, severe fatigue, yellowing of the skin or eyes, chest pain, or significant bleeding to a healthcare professional immediately.

Conclusion

Stivarga represents an important treatment option for certain advanced cancers when other therapies are no longer effective. By targeting multiple pathways involved in cancer growth, it can help manage disease progression and provide additional treatment opportunities for eligible patients. Patients should work closely with their healthcare team to understand the benefits, risks, and monitoring requirements associated with treatment.